



Genomic Cancer
Clinical Trials Initiative

Genomic Cancer Clinical Trials Initiative (GCCTI)

Funded by Cancer Australia

February 2021

Some friendly housekeeping

Purpose of today's workshop

To provide a forum for **Australia's cancer researchers, CTGs,** and the **GCCTI Scientific Steering Group** to discuss opportunities for studies and grants involving **cancers from multiple primary sites and multiple CTGs.**

To **strengthen grant submissions** for the upcoming 2021 rounds, as well as **generating ideas** for grants to submit beyond 2021.

What is the Genomic Cancer Clinical Trials Initiative (GCCTI)?

A **technical service** that aims to support the national cancer cooperative trials groups (CTGs) to develop **mutation-specific** clinical trials concepts and grant applications involving cancers from more than **one primary site and more than one CTG**.

Mutation specific \approx Molecular-specific

GCCTI project team


- **NHMRC Clinical Trials Centre, Sydney**

- Martin Stockler (Chair)
- John Simes
- Chee Lee
- Katrin Sjoquist
- Sonia Yip
- Yeh Chen Lee
- Angelina Tjokrowidjaja
- Martijn Oostendorp

ZEST team

- Helena Knezevic
- Natasha Black
- Sean Darby-Linfitt

GCCTI structure



Scope of the GCCTI from 2018-21

- **Development of mutation-specific clinical trial concepts and protocols** that involve collaboration with more than one CTG and that include more than one cancer type
- **Submission of grant applications** for funding of these trials, including preparation of budgets
- Grants to include **quality of life and pharmaco-economic measures where applicable** (developed collaboratively with the Cancer Australia Chair in Quality of Life and Health Economics Technical Services)
- **Annual workshops** with all CTGs and key stakeholders to identify potential targets for the development of mutation-specific cancer clinical trial protocols

Ongoing Engagement with Technical Services

Cancer Australia Quality of Life Office (QOL)

Cancer Research Economics Support Team (CREST)

Asia Pacific Clinical Oncology Research Development Initiative (ACORD)

Outcomes and benefits

- **Molecularly-focused networks** of researchers, clinicians and scientists
- **Increased capacity** for the conduct of genomic cancer clinical research
- **Strategies for managing challenges** associated with trials of targeted treatments
- **Structures to support conduct** of trials that include multiple primary cancer types and multiple CTGs

How you can be involved

Action	Involvement
Develop concept outlines	 <ul style="list-style-type: none">• Submit ideas/concepts to GCCTI• Work with GCCTI and other CTGs to design trials based on identified concepts
Contribute to idea generation and prioritisation	 <ul style="list-style-type: none">• Attend GCCTI annual workshops• Collaborate with other CTGs, researchers and the GCCTI project team
Input into grant applications	 <ul style="list-style-type: none">• Join grant development teams to develop concept outlines into clinical trials suitable for grant application and ethics approval

GCCTI-supported projects

- SEQUITUR
- EMBRACE



Genomic Cancer
Clinical Trials Initiative

Thank you



Wrap-up and close

- Workshop evaluation survey
- Next steps